What is the Origin of Dyslipidemia in PCOS?

The term combines the Greek prefix dys- meaning bad or difficult, and lipos (fat) with haima (blood), literally meaning abnormal blood fat levels. The clinical association with PCOS was established as early as the mid-20th century when researchers began recognizing the syndrome's metabolic features alongside its reproductive and hyperandrogenic manifestations. This recognition shifted the clinical view of PCOS from purely an ovarian disorder to a complex, systemic endocrinopathy.

What is the Mechanism of Dyslipidemia in PCOS?

The underlying mechanism is strongly linked to the insulin resistance that characterizes a majority of PCOS cases. Hyperinsulinemia stimulates hepatic lipogenesis, increasing the synthesis of very low-density lipoproteins (VLDL), which are triglyceride-rich precursors. Concurrently, insulin resistance impairs the activity of lipoprotein lipase, further hindering triglyceride clearance from the circulation. Furthermore, androgen excess, a hallmark of PCOS, may also contribute to the unfavorable lipid profile, exacerbating the overall atherogenic risk.

Dyslipidemia in PCOS ∞ Area

Dyslipidemia in PCOS

Meaning

Dyslipidemia in Polycystic Ovary Syndrome (PCOS) is a highly prevalent metabolic abnormality characterized by an unfavorable profile of circulating lipids and lipoproteins in women diagnosed with PCOS. This typically involves elevated levels of triglycerides, increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C), contributing significantly to increased cardiovascular risk. This specific endocrine-metabolic overlap necessitates careful clinical management beyond the reproductive symptoms of the syndrome.